Trial Profile
Treatment of Polypoidal Choroidal Vasculopathy With High Dose Ranibizumab (Lucentis): A Phase I Safety Study
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Adverse reactions
- 27 Jun 2016 New trial record